Scott Ericksen Sells 1,500 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 1,500 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the transaction, the chief accounting officer owned 14,946 shares of the company’s stock, valued at $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $162.55 on Wednesday. The business has a fifty day simple moving average of $134.48 and a 200 day simple moving average of $132.39. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $24.59 billion, a price-to-earnings ratio of 29.55, a PEG ratio of 2.72 and a beta of 1.50. Illumina, Inc. has a one year low of $78.79 and a one year high of $165.97.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.2 EPS for the current year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, signaling confidence in further upside for the genomics leader. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are being optimized on Illumina software, a small but constructive development that could reinforce Illumina’s ecosystem in cancer research and data analysis. Business Wire article
• Neutral Sentiment: Recent news about genomics and synthetic biology stocks being in the spotlight highlights ongoing investor interest in the sector, though the coverage did not specifically point to Illumina as a named leader in those articles. Yahoo Finance article
• Neutral Sentiment: Illumina reported strong prior-quarter results, beating EPS and revenue estimates and maintaining FY2026 guidance, which continues to underpin the stock’s fundamental case. MarketBeat article
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, and CAO Scott D. Ericksen also sold stock. While the sales were disclosed and one was under a 10b5-1 plan, the size and frequency of insider selling can weigh on investor sentiment. SEC filing

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ILMN shares. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Piper Sandler lowered their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research report on Monday, February 9th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Thursday, May 14th. Robert W. Baird set a $137.00 price target on Illumina in a research report on Friday, February 6th. Finally, Canaccord Genuity Group lowered their price target on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $138.38.

Institutional Trading of Illumina

A number of large investors have recently bought and sold shares of ILMN. Glenmede Trust Co. NA grew its holdings in shares of Illumina by 6.5% during the first quarter. Glenmede Trust Co. NA now owns 2,288 shares of the life sciences company’s stock worth $282,000 after purchasing an additional 140 shares during the last quarter. Groupama Asset Managment grew its holdings in shares of Illumina by 3.7% during the first quarter. Groupama Asset Managment now owns 9,545 shares of the life sciences company’s stock worth $1,177,000 after purchasing an additional 340 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Illumina by 1.4% during the first quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after purchasing an additional 29,094 shares during the last quarter. Bull Harbor Capital LLC bought a new stake in shares of Illumina during the first quarter worth $1,413,000. Finally, Arkadios Wealth Advisors grew its holdings in shares of Illumina by 1.6% during the first quarter. Arkadios Wealth Advisors now owns 8,001 shares of the life sciences company’s stock worth $986,000 after purchasing an additional 124 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.